Faeth与Sensei合并上市，通过股票销售净赚2亿美元
Faeth goes public in merger with Sensei, nets $200M in stock sale
生命科学资讯
生物技术与制药领域的最新动态
FDA转变立场，将审查莫德纳流感疫苗。
FDA reverses course, will review Moderna’s flu vaccine
礼来以1亿美元预付款获得CSL的IL-6免疫炎症抗体许可。
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Paragon新生物技术公司Korsana挑战阿尔茨海默病，与罗氏一较高下。
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Paragon最新生物技术将尝试像罗氏一样延缓阿尔茨海默病进程——Endpoints新闻
Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News
利奥制药宣布七年来首次实现盈利。
Leo Pharma says it's turned a profit for the first time in seven years
Moderna在Arbutus的mRNA专利战中遭遇挫折。
Moderna faces setback in Arbutus' mRNA patent fight
解锁健康数据
Unlocking health data
FDA拒绝Disc Medicine罕见病药物，尽管已授予其专员凭证。
FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
六家生物科技公司递交港交所上市申请；法拉第制药公司关闭运营
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters
康帕斯通路公司因第二阶段抑郁症治疗突破股价飙升
Compass Pathways soars on second Phase 3 depression hit
Ocular Therapeutix公司Axpaxli疗效优于Eylea，股价应声下跌。
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink
勃林格殷格翰停止吸入式囊性纤维化基因疗法研发。
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy
Moderna与FDA之争；赛诺菲CEO保罗·哈德森离职；临床试验为何如此昂贵；及其他动态
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
吉利德以8000万美元预付款从中国基石药业引进抗癌药物。
Gilead gets cancer drug from China-based Genhouse for $80M upfront
五角大楼将药明康德列入中国军方关联企业名单后又移除。
Pentagon adds, then withdraws, WuXi AppTec to Chinese military list
礼来就retatrutide分类裁决提起上诉，此案或影响复方制剂行业。
Lilly appeals retatrutide classification ruling in case that could impact compounders
表观遗传编辑初创公司Moonwalk转向siRNA技术应对肥胖问题
Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity
灵北偏头痛预防药物二期试验成功，推动新疗法类别进展。
Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class
Moderna流感疫苗困境令2028年盈亏平衡指引蒙上阴影。
Moderna's flu shot dilemma muddies 2028 break-even guidance